Instrument Inactif

Autres langues Big Cypress Acquisition Corp. Nasdaq

Actions

BCYPU

US0891152086

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION - Form 8-K	28/10/21
Big Cypress Acquisition Corp.(NasdaqCM:BCYP) dropped from NASDAQ Composite Index	22/10/21
SAB Biotherapeutics, Inc. completed the acquisition of Big Cypress Acquisition Corp. in a reverse merger transaction.	22/10/21
BIG CYPRESS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders (form 8-K)	21/10/21
Big Cypress Acquisition Corp. Announces Board Changes	21/10/21
Big Cypress Acquisition Corp. : Stockholders Approve Business Combination with SAB Biotherapeutics	21/10/21
SAB Corporate Presentation	15/10/21
BIG CYPRESS ACQUISITION CORP. : Other Events (form 8-K)	13/10/21
R&D Day Presentation	13/10/21
BIG CYPRESS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12/10/21
Big Cypress Acquisition : SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021	06/10/21
Big Cypress Acquisition : SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19	04/10/21
SAB Biotherapeutics : Appoints Russell Beyer Chief Financial Officer	28/09/21
SAB Biotherapeutics: SAB-185 zur Behandlung von COVID-19 erhält positive DSMB-Stellungnahme und erreicht Phase 3 in NIH-gesponserter Studie ACTIV-2	25/09/21
SAB Biotherapeutics : anuncia la revisión positiva del DSMB para SAB-185, que pasa a la fase 3 en el ensayo ACTIV-2 patrocinado por los NIH para el tratamiento de la COVID-19	24/09/21
SAB Biotherapeutics : Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19	24/09/21
Big Cypress Acquisition Corp : Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics	23/09/21
Big Cypress Acquisition : SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19	22/09/21
SAB Biotherapeutics : Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza	15/09/21
SAB Biotherapeutics : to Present at Upcoming September Virtual Investor Conferences	08/09/21

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Big Cypress Acquisition Corp. Nasdaq

Actions

BCYPU

US0891152086

Autres langues

Filtres